Intravenous Dexamethasone and Dexmedetomidine on the Analgesic Efficacy of Erector Spinae Plane Block

Sponsor
Huazhong University of Science and Technology (Other)
Overall Status
Completed
CT.gov ID
NCT04767256
Collaborator
(none)
120
1
2
10
12

Study Details

Study Description

Brief Summary

Patients having lumbar spinal fusion often complain about severe postoperative pain and postoperative rehabilitation process can be affected negatively. Postoperative pain that cannot be well controlled may lead to delayed mobilization, pulmonary and thromboembolic complications, prolonged hospital stays, and chronic pain syndromes. Pain after spinal surgery can arise from several different tissues, such as the vertebrae, disks, ligaments, dura, facet joint, muscle, fascia, and subcutaneous and cutaneous tissues.

Ultrasound-guided lumbar erector spinae plane block (ESPB) has been shown to reduce postoperative pain in patients undergoing posterior lumbar interbody fusion (PLIF). However, the duration of analgesia after single-shot ESPB with commonly used local anesthetics is reported to be no more than 12 h, which often not long enough to provide satisfactory postoperative pain relief, as the pain typically lasts for several days. Compared with perineural route, intravenous additives to local anesthetics are commonly accepted as its safety and efficiency have been reported. Moreover, co-administration of intravenous dexamethasone and dexmedetomidine significantly prolonged the time to first rescue analgesic request after single-shot interscalene brachial plexus block. However, more data are needed especially for lumbar ESPB.

Condition or Disease Intervention/Treatment Phase
  • Drug: Dexamethasone and dexmedetomidine
  • Drug: Dexmedetomidine
  • Other: Ultrasound-guided lumbar erector spinae plane block
  • Other: PCIA
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Intravenous Dexamethasone and Dexmedetomidine on the Analgesic Efficacy of Erector Spinae Plane Block for Posterior Lumbar Interbody Fusion Surgery
Actual Study Start Date :
Mar 1, 2021
Actual Primary Completion Date :
Aug 22, 2021
Actual Study Completion Date :
Dec 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: DD group

co-administered intravenous dexamethasone 10 mg and dexmedetomidine 1 ug/kg

Drug: Dexamethasone and dexmedetomidine
General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.

Other: Ultrasound-guided lumbar erector spinae plane block
The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were first visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.

Other: PCIA
Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.

Placebo Comparator: D group

intravenous dexmedetomidine 1 ug/kg

Drug: Dexmedetomidine
Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.

Other: Ultrasound-guided lumbar erector spinae plane block
The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were first visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.

Other: PCIA
Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.

Outcome Measures

Primary Outcome Measures

  1. The cumulative opioid consumption [At 24 postoperative hours]

  2. The time to first rescue analgesic request [Up to 48 postoperative hrs]

Secondary Outcome Measures

  1. The pain scores determined by the numeric rating scale (NRS, 0-10) [At 6, 12, 18, 24, 30, 36, 42, and 48 hrs after the surgery]

  2. Incidence of postoperative nausea and vomiting [Up to 24 postoperative hrs]

  3. Postoperative hospital length of stay [Up to 3 weeks]

  4. Adverse events [Up to 48 postoperative hrs]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 18-65 yrs

  2. American Society of Anesthesiologists physical statusⅠ-Ⅲ

  3. Involvement of ≤3 spinal levels

  4. Undergo elective posterior lumbar interbody fusion

  5. Informed consent

Exclusion Criteria:
  1. A known allergy to the drugs being used

  2. Pre-existing neuropsychiatric disorders or language barrier

  3. Analgesics intake, history of substance abuse

  4. Contraindications to peripheral nerve block

  5. Acute cerebrovascular disease

  6. Severe liver failure

  7. Uncontrolled low blood pressure

  8. Sinus bradycardia or atrioventricular block

Contacts and Locations

Locations

Site City State Country Postal Code
1 Union Hospital Wuhan Hubei China

Sponsors and Collaborators

  • Huazhong University of Science and Technology

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xi Wu, Principal Investigator, Department of Anesthesiology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
ClinicalTrials.gov Identifier:
NCT04767256
Other Study ID Numbers:
  • XH20210202
First Posted:
Feb 23, 2021
Last Update Posted:
Mar 29, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 29, 2022